Literature DB >> 10681375

Metabolism and excretion of [(14)C]celecoxib in healthy male volunteers.

S K Paulson1, J D Hribar, N W Liu, E Hajdu, R H Bible, A Piergies, A Karim.   

Abstract

We determined the disposition of a single 300-mg dose of [(14)C]celecoxib in eight healthy male subjects. The [(14)C]celecoxib was administered as a fine suspension reconstituted in 80 ml of an apple juice/Tween 80/ethanol mixture. Blood and saliva samples were collected at selected time intervals after dosing. All urine and feces were collected on the 10 consecutive days after dose administration. Radioactivity in each sample was determined by liquid scintillation counting or complete oxidation and liquid scintillation counting. Metabolic profiles in plasma, urine, and feces were obtained by HPLC, and metabolites were identified by mass spectrometry and NMR. [(14)C]Celecoxib was well absorbed, reaching peak plasma concentrations within 2 h of dosing. [(14)C]Celecoxib was extensively metabolized, with only 2.56% of the radioactive dose excreted as celecoxib in either urine or feces. The total percentage of administered radioactive dose recovered was 84.8 +/- 4.9%, with 27.1 +/- 2.2% in the urine and 57.6 +/- 7.3% in the feces. The oxidative metabolism of celecoxib involved hydroxylation of celecoxib at the methyl moiety followed by further oxidation of the hydroxyl group to form a carboxylic acid metabolite. The carboxylic acid metabolite of celecoxib was conjugated with glucuronide to form the 1-O-glucuronide. The percentages of the dose excreted in the feces as celecoxib and the carboxylic acid metabolite were 2.56 +/- 1.09 and 54.4 +/- 6.8%, respectively. The majority of the dose excreted in the urine was the carboxylic acid metabolite (18.8 +/- 2.1%); only a small amount was excreted as the acyl glucuronide (1.48 +/- 0.15%).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10681375

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  31 in total

1.  Prediction of the effects of genetic polymorphism on the pharmacokinetics of CYP2C9 substrates from in vitro data.

Authors:  Makiko Kusama; Kazuya Maeda; Koji Chiba; Akinori Aoyama; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2008-12-12       Impact factor: 4.200

2.  In vitro and in vivo evaluation of proniosomes containing celecoxib for oral administration.

Authors:  Mohamed Nasr
Journal:  AAPS PharmSciTech       Date:  2010-01-08       Impact factor: 3.246

Review 3.  Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain.

Authors:  D Clemett; K L Goa
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

Review 4.  The Role of Alcohol Dehydrogenase in Drug Metabolism: Beyond Ethanol Oxidation.

Authors:  Li Di; Amanda Balesano; Samantha Jordan; Sophia M Shi
Journal:  AAPS J       Date:  2021-01-07       Impact factor: 4.009

5.  Integration analysis of metabolites and single nucleotide polymorphisms improves the prediction of drug response of celecoxib.

Authors:  Xiaoqing Xing; Pengcheng Ma; Qing Huang; Xiemin Qi; Bingjie Zou; Jun Wei; Lei Tao; Lingjun Li; Guohua Zhou; Qinxin Song
Journal:  Metabolomics       Date:  2020-03-14       Impact factor: 4.290

6.  Cyclo-oxygenase-2 inhibitors : beneficial or detrimental for athletes with acute musculoskeletal injuries?

Authors:  Stuart J Warden
Journal:  Sports Med       Date:  2005       Impact factor: 11.136

Review 7.  Clinical use and pharmacological properties of selective COX-2 inhibitors.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2007-11-13       Impact factor: 2.953

8.  Quantitation of celecoxib and four of its metabolites in rat blood by UPLC-MS/MS clarifies their blood distribution patterns and provides more accurate pharmacokinetics profiles.

Authors:  Yong Ma; Song Gao; Ming Hu
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2015-07-19       Impact factor: 3.205

Review 9.  [Clinical pharmacology of the selective COX-2 inhibitors].

Authors:  M Burian; G Geisslinger
Journal:  Orthopade       Date:  2003-12       Impact factor: 1.087

10.  Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa.

Authors:  Stefano Fiorucci; Luca Santucci; John L Wallace; Marco Sardina; Mario Romano; Piero del Soldato; Antonio Morelli
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.